잎새버섯
Maitake Mushroom
📚 관련 논문 (16편)
1. J Nutr Sci Vitaminol (Tokyo). 2026;72(2):163-175. doi: 10.3177/jnsv.72.163. Maitake Mushroom (Grifola frondosa) Enhances Cognitive Function in Healthy Older Japanese: A Randomized, Double-Blind, Placebo-Controlled Trial. Jogi EM(1), Kato MC(1), Masuda Y(2), Konishi M(2), Kuwabara N(3), Sato S(
2. J Evid Based Complementary Altern Med. 2017 Oct;22(4):667-674. doi: 10.1177/2156587217708524. Epub 2017 May 22. Induction Effect to Apoptosis by Maitake Polysaccharide: Synergistic Effect of Its Combination With Vitamin C in Neuroglioma Cell. Duan L(1)(2)(3), Wu XL(3), Zhao F(1)(2)(4), Zeng R
3. Integr Cancer Ther. 2017 Jun;16(2):205-214. doi: 10.1177/1534735416644674. Epub 2016 May 5. Synergistic Apoptotic Effect of D-Fraction From Grifola frondosa and Vitamin C on Hepatocellular Carcinoma SMMC-7721 Cells. Zhao F(1)(2)(3), Wang YF(4), Song L(2), Jin JX(5), Zhang YQ(2), Gan HY(2), Ya
4. J Leukoc Biol. 2015 Dec;98(6):1015-25. doi: 10.1189/jlb.1A0814-415RR. Epub 2015 Aug 21. Soluble β-glucan from Grifola frondosa induces tumor regression in synergy with TLR9 agonist via dendritic cell-mediated immunity. Masuda Y(1), Nawa D(2), Nakayama Y(2), Konishi M(2), Nanba H(2). Author i
5. Integr Cancer Ther. 2013 Sep;12(5):442-8. doi: 10.1177/1534735412473643. Epub 2013 Jan 22. Induction of cell death in renal cell carcinoma with combination of D-fraction and vitamin C. Alexander B(1), Fishman AI, Eshghi M, Choudhury M, Konno S. Author information: (1)New York Medical College
6. Cancer Immunol Immunother. 2010 Jun;59(6):885-97. doi: 10.1007/s00262-009-0815-3. Epub 2010 Feb 6. Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity. Lin H(1), de Stanchina E, Zhou XK, Hong F, Seidman A, Fornier M,
7. BJU Int. 2010 Apr;105(7):1011-5. doi: 10.1111/j.1464-410X.2009.08870.x. Epub 2009 Sep 4. Synergistic potentiation of interferon activity with maitake mushroom d-fraction on bladder cancer cells. Louie B(1), Rajamahanty S, Won J, Choudhury M, Konno S. Author information: (1)Department of Urol
8. J Soc Integr Oncol. 2009 Spring;7(2):66-72. Maitake mushroom (Grifola frondosa): systematic review by the natural standard research collaboration. Ulbricht C(1), Weissner W, Basch E, Giese N, Hammerness P, Rusie-Seamon E, Varghese M, Woods J. Author information: (1)Massachusetts General Hosp
9. Appl Microbiol Biotechnol. 2020 Jun;104(11):4675-4703. doi: 10.1007/s00253-020-10476-4. Epub 2020 Apr 9. Mushroom extracts and compounds with suppressive action on breast cancer: evidence from studies using cultured cancer cells, tumor-bearing animals, and clinical trials. Wong JH(1), Ng TB(
1. Cancer Immunol Immunother. 2015 Feb;64(2):237-47. doi: 10.1007/s00262-014-1628-6. Epub 2014 Oct 29. Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study. Wesa KM(1), Cunningham-Rundles S, Klimek VM, Vertosick E, Coleton MI, Yeung KS, Lin H, Nimer S, Cassileth BR. Author information: (1)Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA. BACKGROUND: Myelodysplastic syndromes (MDS) are characterized by ineffective erythropoiesis with dysplastic bone marrow leading to peripheral cytopenia, risk of infection, and progression to acute myelogenous leukemia. Maitake mushroom beta-glucan, a dietary supplement, stimulates hematopoietic progenitor cell differentiation, granulocyte colony-stimulating factor production, and recovery of peripheral blood leukocytes after bone marrow injury. This phase II trial examined the effects of Maitake on innate immune function in MDS. METHODS: Myelodysplastic syndromes patients with International Prognostic Scoring System Low- and Intermediate-1-risk disease received oral Maitake extract at 3 mg/kg twice daily for 12 weeks. Primary endpoints included neutrophil count and function tested as endogenous or stimulated neutrophil production of reactive oxygen species (ROS) by flow cytometry compared with age-matched healthy controls (HC). ROS activators were Escherichia coli, phorbol ester, and the bacterial peptide N-formylmethionyl-leucyl-phenylalanine (fMLP). Complete blood counts, chemistry panels, iron studies, and monocyte function were evaluated. RESULTS: Of 21 patients enrolled, 18 completed the study and were evaluable. Maitake increased endogenous (basal) neutrophil (p = 0.005) and monocyte function (p = 0.021). Pre-treatment monocyte response to E. coli was reduced in MDS patients compared with HC (p = 0.002) and increased (p = 0.0004) after treatment. fMLP-stimulated ROS production response also increased (p = 0.03). Asymptomatic eosinophilia occurred in 4 patients (p = 0.014). Other changes in albumin, hemoglobin, and total protein were not clinically relevant. CONCLUSIONS: Maitake was well tolerated. Enhanced in vitro neutrophil and monocyte function following treatment demonstrate that Maitake has beneficial immunomodulatory potential in MDS. Further study is warranted. DOI: 10.1007/s00262-014-1628-6 PMCID: PMC4317517 PMID: 25351719 [Indexed for MEDLINE] Conflict of interest statement: The authors declare that they have no conflict of interest.
2. J Cancer Res Clin Oncol. 2009 Sep;135(9):1215-21. doi: 10.1007/s00432-009-0562-z. Epub 2009 Mar 1. A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. Deng G(1), Lin H, Seidman A, Fornier M, D'Andrea G, Wesa K, Yeung S, Cunningham-Rundles S, Vickers AJ, Cassileth B. Author information: (1)Integrative Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. dengg@mskcc.org BACKGROUND: Cancer patients commonly use dietary supplements to "boost immune function". A polysaccharide extract from Grifola frondosa (Maitake extract) showed immunomodulatory effects in preclinical studies and therefore the potential for clinical use. Whether oral administration in human produces measurable immunologic effects, however, is unknown. METHODS: In a phase I/II dose escalation trial, 34 postmenopausal breast cancer patients, free of disease after initial treatment, were enrolled sequentially in five cohorts. Maitake liquid extract was taken orally at 0.1, 0.5, 1.5, 3, or 5 mg/kg twice daily for 3 weeks. Peripheral blood was collected at days -7, 0 (prior to the first dosing), 7, 14, and 21 for ex vivo analyses. The primary endpoints were safety and tolerability. RESULTS: No dose-limiting toxicity was encountered. Two patients withdrew prior to completion of the study due to grade I possibly related side effects: nausea and joint swelling in one patient; rash and pruritus in the second. There was a statistically significant association between Maitake and immunologic function (p < 0.0005). Increasing doses of Maitake increased some immunologic parameters and depressed others; the dose-response curves for many endpoints were non-monotonic with intermediate doses having either immune enhancing or immune suppressant effects compared with both high and low doses. CONCLUSIONS: Oral administration of a polysaccharide extract from Maitake mushroom is associated with both immunologically stimulatory and inhibitory measurable effects in peripheral blood. Cancer patients should be made aware of the fact that botanical agents produce more complex effects than assumed, and may depress as well as enhance immune function. DOI: 10.1007/s00432-009-0562-z PMCID: PMC3751581 PMID: 19253021 [Indexed for MEDLINE]
3. J Ethnopharmacol. 2021 Nov 15;280:114395. doi: 10.1016/j.jep.2021.114395. Epub 2021 Jul 13. Antitumor activities of Grifola frondosa (Maitake) polysaccharide: A meta-analysis based on preclinical evidence and quality assessment. Zhao F(1), Guo Z(2), Ma ZR(3), Ma LL(4), Zhao J(5). Author information: (1)Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, China; Key Laboratory of Environmental Ecology and Population Health in Northwest Minority Areas, Medical College of Northwest Minzu University, Lanzhou, China. Electronic address: runfor710@163.com. (2)Key Laboratory of Environmental Ecology and Population Health in Northwest Minority Areas, Medical College of Northwest Minzu University, Lanzhou, China. Electronic address: 251610780@qq.com. (3)Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, China. Electronic address: mzr@xbmu.edu.cn. (4)Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, China; College of Life Science and Engineering, Northwest Minzu University, Lanzhou, China. Electronic address: malingli90@163.com. (5)Key Laboratory of Environmental Ecology and Population Health in Northwest Minority Areas, Medical College of Northwest Minzu University, Lanzhou, China. Electronic address: gz6768@163.com. ETHNOPHARMACOLOGICAL RELEVANCE: The antitumor effects of Grifola frondosa/maitake polysaccharide (GFP) have been reported in many preclinical studies, especially in vivo experiments. The present meta-analysis aimed to provide an in vivo evidence and theoretical basis for future clinical trials by assessing the efficacy and underlying mechanisms of GFP in tumor treatment. MATERIALS AND METHODS: English and Chinese databases were examined to include animal experiments to study the antitumor activity of GFP. Literature screening, data extraction, and meta-analysis were conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. In addition, the Systematic Review Center for Laboratory animal Experimentation (SYRCLE) risk of bias (RoB) tool was used to assess the risk of bias of the included animal studies. RESULTS: Potentially relevant studies (442) were identified, and finally 24 eligible studies (all in English) were included. The meta-analysis revealed that GFP has significant effects in inhibiting tumor growth (high dose: mean difference (MD) = -1.34, 95% confidence interval (CI) = [-1.73, -0.95]; low dose: MD = -5.68, 95% CI = [-7.27, -4.09]), improving tumor remission rate (odds ratio = 25.59, 95% CI = [9.08, 72.11]), and enhancing immune function in both cellular (CD4+ T cell percentage: MD = 3.03, 95% CI = [1.16, 4.90]; CD8+ T cell percentage: MD = 1.10, 95% CI = [-0.29, 2.49]) and humoral immunity (MD and [95% CI] of interleukin (IL)-2, IL-12 and tumor necrosis factor-α were 7.86 [6.29, 9.44], 35.95 [5.18, 66.72], and 10.03 [8.71, 11.36], respectively), and the differences between the two groups of the above indicators were statistically significant (all P < 0.01) except CD8+ T cell percentage. Additionally, the quality of the included studies was not high, and the risk of bias mainly concentrated on selection, detection, and reporting biases. CONCLUSION: GFP is a potential candidate for tumor treatment and clinical trials. TRIAL REGISTRATION: The review protocol for this study was registered with the PROSPERO database before beginning the review process (CRD42018108897). Copyright © 2021 Elsevier B.V. All rights reserved. DOI: 10.1016/j.jep.2021.114395 PMID: 34271115 [Indexed for MEDLINE]
4. Curr Oncol Rep. 2023 Jun;25(6):569-587. doi: 10.1007/s11912-023-01408-2. Epub 2023 Mar 30. Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies. Narayanan S(1), de Mores AR(2), Cohen L(2), Anwar MM(3), Lazar F(4), Hicklen R(5), Lopez G(2), Yang P(2), Bruera E(2). Author information: (1)Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. snarayanan2@mdanderson.org. (2)Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. (3)Department of Biotechnology, Institute of Graduate Studies and Research (IGSR), Alexandria University, Alexandria, Egypt. (4)São Paulo Câncer Institute (ICESP), São Paulo, Brazil. (5)Research Medical Library, UT MD Anderson Cancer Center, Houston, TX, USA. PURPOSE OF REVIEW: Patients seek clinical guidance on mushroom supplements that can be given alongside conventional treatments, but most research on such fungi has been preclinical. The current systematic review focused on clinical studies of mushrooms in cancer care conducted in the past 10 years. We searched Medline (Ovid), Embase (Ovid), Scopus (Wiley), and Cochrane Library to identify all mushroom studies conducted in humans published from January 2010 through December 2020. Two authors independently assessed papers for inclusion. RECENT FINDINGS: Of 136 clinical studies identified by screening 2349, 39 met inclusion criteria. The studies included 12 different mushroom preparations. A survival benefit was reported using Huaier granules (Trametes robiniophila Murr) in 2 hepatocellular carcinoma studies and 1 breast cancer study. A survival benefit was also found in 4 gastric cancer studies using polysaccharide-K (polysaccharide-Kureha; PSK) in the adjuvant setting. Eleven studies reported a positive immunological response. Quality-of-life (QoL) improvement and/or reduced symptom burden was reported in 14 studies using various mushroom supplements. Most studies reported adverse effects of grade 2 or lower, mainly nausea, vomiting, diarrhea, and muscle pain. Limitations included small sample size and not using randomized controlled trial design. Many of the reviewed studies were small and observational. Most showed favorable effects of mushroom supplements in reducing the toxicity of chemotherapy, improving QoL, favorable cytokine response, and possibly better clinical outcomes. Nevertheless, the evidence is inconclusive to recommend the routine use of mushrooms for cancer patients. More trials are needed to explore mushroom use during and after cancer treatment. © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. DOI: 10.1007/s11912-023-01408-2 PMID: 36995535 [Indexed for MEDLINE]
5. Acta Biochim Pol. 2022 Sep 7;69(3):625-632. doi: 10.18388/abp.2020_5996. Effect of Maitake D-fraction in advanced laryngeal and pharyngeal cancers during concurrent chemoradiotherapy: A randomized clinical trial. Hu Q(1), Xie B(1). Author information: (1)Department of Otolaryngology, Wuxi No.2 People's Hospital, No. 68 Zhongshan Road, Wuxi 214002, Jiangsu, China. BACKGROUND: Concurrent chemo-radiotherapy (CCRT) is an ideal treatment for advanced head and neck squamous cell carcinoma (HNSCC). The performance of CCRT induces severe toxicities in HNSCC patients and decreases the quality of life (QOL). Maitake D-Fraction is proteoglycan which has anti-tumor function associated with its immunomodulatory capacity. The polysaccharides of Maitake also have anti-radiation effect in radiation therapy during cancer treatment. This research aimed to illustrate Maitake D-Fraction effects on CCRT-associated adverse events and QOL. METHODS: During CCRT, Maitake capsules were taken orally 3 times a day, each time 4 capsules, one hour before meals. QOL were analyzed by EORTC QLQ-C30-Chinese version and EORTC QLQ-HandN-35-Chinese version. 141 patients were recruited and divided into an intervention group and a placebo group. RESULTS: Frequencies of severe CCRT-associated adverse events in intervention group were less than in placebo group. Global QOL score in intervention group was higher than in placebo group 5 weeks post treatment. The proportion of patients returning to baseline global QOL score at 6-month was increased by Maitake D-Fraction administration. CONCLUSION: In conclusion, this randomized clinical trial demonstrated that in advanced laryngeal and pharyngeal cancer patients, the oral administration of Maitake D-Fraction alleviated CCRT-related adverse events and deterioration in QOL. DOI: 10.18388/abp.2020_5996 PMID: 36070433 [Indexed for MEDLINE]
6. J Altern Complement Med. 2010 Dec;16(12):1295-9. doi: 10.1089/acm.2009.0696. Epub 2010 Oct 29. Maitake mushroom (Grifola frondosa) extract induces ovulation in patients with polycystic ovary syndrome: a possible monotherapy and a combination therapy after failure with first-line clomiphene citrate. Chen JT(1), Tominaga K, Sato Y, Anzai H, Matsuoka R. Author information: (1)Department of Gynecology, J.T. Chen Clinic, Tokyo, Japan. chin-cl@coffee.ocn.ne.jp BACKGROUND: Insulin resistance is a prominent feature of polycystic ovary syndrome (PCOS), and insulin-sensitizing drugs are used to induce ovulation. Recently, it was reported that an extract from Maitake mushroom (Grifola frondosa) improves insulin resistance. OBJECTIVES: The objective was to explore the effects of Maitake extract (SX-fraction: MSX) to induce ovulation in patients with PCOS in comparison with and in combination with clomiphene citrate (CC). DESIGN: We conducted an open trial with 80 patients with PCOS at three clinics in Japan. Seventy-two (72) new patients were randomly assigned to receive MSX or CC monotherapy for up to 12 weeks. Eighteen (18) patients who did not respond to MSX or CC were subjected to combination therapy of MSX and CC for up to 16 weeks. Eight (8) patients with documented history of failure to CC received combination therapy from the beginning. Ovulation was assessed by ultrasonography. RESULTS: Twenty-six (26) patients in the MSX group and 31 in the CC group were evaluated for ovulation. The ovulation rates for MSX and CC were as follows: 76.9% (20/26) and 93.5% (29/31), respectively by the patients (NS), and 41.7% (30/72) and 69.9% (58/83), respectively, by the cycles (p = 0.0006). In the combination therapy, 7 of 7 patients who failed in MSX monotherapy and 6 of 8 patients who failed in CC monotherapy showed ovulation. CONCLUSIONS: The present study suggests that MSX alone may induce ovulation in PCOS patients and may be useful as an adjunct therapy for patients who failed first-line CC treatment. DOI: 10.1089/acm.2009.0696 PMID: 21034160 [Indexed for MEDLINE]
7. Altern Ther Health Med. 1996 Sep;2(5):62-6. The effect of maitake mushrooms on liver and serum lipids. Kubo K(1), Nanba H. Author information: (1)Department of Microbial Chemistry, Kobe Pharmaceutical University, Japan. OBJECTIVE: To determine the efficacy of maitake mushrooms in inhibiting the elevation of liver and serum lipids in rats. DESIGN: Sprague-Dawley rats with hyperlipidemia were used to measure and compare the values of cholesterol, phospholipids, and triglycerides between cholesterol-fed rats and rats whose diets were fortified with 20% maitake mushroom dried powder. RESULTS: The values in maitake-fed rats were consistently less than those in the basic cholesterol-fed rats. The value of high-density lipoprotein cholesterol, which usually is decreased by taking high-cholesterol feed, maintained the level that it had at the beginning of the experiment. Weights of extirpated liver and epididymal fat pads were significantly less than those in the basic feed group. CONCLUSION: Our data suggest that maitake mushrooms have the ability to alter lipid metabolism by inhibiting both the accumulation of liver lipids and the elevation of serum lipids. Further studies are needed to elucidate the mechanism of activity of maitake mushrooms and to establish whether their action in humans is similar to that in the animal model tested here. PMID: 8795938 [Indexed for MEDLINE]
⚠️ 면책 고지
이 정보는 일반 교육 목적이며 의료 진단/처방을 대체하지 않습니다.